During the MPN Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss the place of bone marrow transplant (BMT), as well as BMT reporting consistency. Alessandro Vannucchi delivered a presentation on use of BMT in myelofibrosis (MF), including strategies to optimize the outcomes of BMT and considerations to be made for special populations.
Vannucchi discusses the increase trend for the use of allogenic hematopoietic stem cell transplant (allo-HSCT) in patients, as well as the age of patients with MF who may be eligible. They highlight the importance of considering the risks and benefits of transplant, consideration comorbidities, and early transplant where possible. This presentation concludes with a discussion on the impact of TP53 mutations and accelerated vs blast phase MF in special populations.
Негізгі бет Reconsidering the place of bone marrow transplant (BMT), and BMT reporting consistency
Пікірлер